X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs NOVARTIS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA NOVARTIS SUN PHARMA/
NOVARTIS
 
P/E (TTM) x 24.9 398.8 6.2% View Chart
P/BV x 2.6 31.9 8.2% View Chart
Dividend Yield % 0.5 1.4 33.6%  

Financials

 SUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
NOVARTIS
Mar-18
SUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs701758 92.4%   
Low Rs433579 74.8%   
Sales per share (Unadj.) Rs110.4228.4 48.3%  
Earnings per share (Unadj.) Rs11.031.7 34.6%  
Cash flow per share (Unadj.) Rs17.232.8 52.6%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.41.5 23.6%  
Book value per share (Unadj.) Rs158.8297.1 53.4%  
Shares outstanding (eoy) m2,399.2624.69 9,717.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 175.4%   
Avg P/E ratio x51.621.1 245.2%  
P/CF ratio (eoy) x32.920.4 161.2%  
Price / Book Value ratio x3.62.2 158.7%  
Dividend payout %18.231.5 57.8%   
Avg Mkt Cap Rs m1,360,02116,505 8,239.9%   
No. of employees `00017.80.7 2,663.0%   
Total wages/salary Rs m53,6711,445 3,713.5%   
Avg. sales/employee Rs Th14,890.98,441.3 176.4%   
Avg. wages/employee Rs Th3,017.12,163.6 139.4%   
Avg. net profit/employee Rs Th1,480.61,173.1 126.2%   
INCOME DATA
Net Sales Rs m264,8955,639 4,697.7%  
Other income Rs m8,3881,718 488.1%   
Total revenues Rs m273,2827,357 3,714.5%   
Gross profit Rs m56,081-63 -89,730.1%  
Depreciation Rs m14,99825 59,282.2%   
Interest Rs m5,17655 9,359.3%   
Profit before tax Rs m44,2951,575 2,812.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452792 1,067.7%   
Profit after tax Rs m26,338784 3,361.1%  
Gross profit margin %21.2-1.1 -1,910.1%  
Effective tax rate %19.150.3 38.0%   
Net profit margin %9.913.9 71.5%  
BALANCE SHEET DATA
Current assets Rs m316,3599,522 3,322.6%   
Current liabilities Rs m198,6433,296 6,026.8%   
Net working cap to sales %44.4110.4 40.3%  
Current ratio x1.62.9 55.1%  
Inventory Days Days9537 259.0%  
Debtors Days Days10828 378.9%  
Net fixed assets Rs m213,17846 463,430.7%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m378,6067,213 5,248.9%   
Net worth Rs m381,0067,336 5,193.4%   
Long term debt Rs m17,7210-   
Total assets Rs m643,02811,105 5,790.3%  
Interest coverage x9.629.5 32.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 81.1%   
Return on assets %4.97.6 64.9%  
Return on equity %6.910.7 64.7%  
Return on capital %10.022.2 45.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81661 67,353.8%   
Fx outflow Rs m30,1433,630 830.4%   
Net fx Rs m10,673-3,570 -299.0%   
CASH FLOW
From Operations Rs m39,0721,610 2,427.0%  
From Investments Rs m-33,708687 -4,906.6%  
From Financial Activity Rs m-15,393-2,677 575.1%  
Net Cashflow Rs m-7,359-380 1,938.6%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 2.0 256.5%  
FIIs % 23.0 1.6 1,437.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.5 38.6%  
Shareholders   133,026 41,647 319.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 24, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS